Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma

SIMPLE SUMMARY: Management of hepatocellular carcinoma is a rapidly evolving field, with atezolizumab-bevacizumab recently becoming standard of care after showing survival benefit over sorafenib. However, all clinical trials evaluating drugs approved in the second line setting, such as cabozantinib,...

Descripción completa

Detalles Bibliográficos
Autores principales: Storandt, Michael H., Gile, Jennifer J., Palmer, Mathias E., Zemla, Tyler J., Ahn, Daniel H., Bekaii-Saab, Tanios S., Jin, Zhaohui, Tran, Nguyen H., Mahipal, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657200/
https://www.ncbi.nlm.nih.gov/pubmed/36358592
http://dx.doi.org/10.3390/cancers14215173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657200/
https://www.ncbi.nlm.nih.gov/pubmed/36358592
http://dx.doi.org/10.3390/cancers14215173

Ejemplares similares